B
Bull
Bull · 25%ANL
$2.06
Scenario price
$10.640
+0.266 (+2.50%)At close
Loading chart…
- High
- 11.320
- Open
- 10.370
- VWAP
- 10.78
- Volume
- 242.56K
- Mkt Cap
- 136.89M
- Low
- 10.370
- Amount
- 2.61M
- EV/EBITDA, TTM
- -245.73
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.
AI analysis of Adlai Nortye Group Ltd (ANL)
HoldAdlai Nortye Ltd (ANL) is currently not a good buy due to its very low RSI of 28.408, indicating that it is oversold, and a significant 5-day price drop of 29.39%. While it has shown impressive year-to-date growth of 699.28%, the recent sharp decline raises concerns. The main risk is the negative earnings per share forecast, with a projected EPS of -0.54 for Q4 2024, which could impact investor sentiment.
Valuation Metrics
The current forward P/E ratio for Adlai Nortye Group Ltd (ANL) is 0.00, compared to its 5-year average forward P/E of -4.27.
Alphio AI Price Scenarios for ANL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ANL
Events Timeline
News
9.009-08NASDAQ.COMAdlai Nortye Initiates Global Phase I Trial for AN4035
8.509-08NewsfilterFirst-in-Class CEACAM5-Targeting ADC Clinical Trial Initiated
- 9.508-14Newsfilter
Adlai Nortye Reports H1 2026 Financial Results and Clinical Updates
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
9.507-07NASDAQ.COMInnovative Eyewear Reports Significant Q2 Sales Growth
ANL FAQ — answered by Alphio AI
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. It operates in the Healthcare sector.
Adlai Nortye Ltd (ANL) is currently not a good buy due to its very low RSI of 28.408, indicating that it is oversold, and a significant 5-day price drop of 29.39%. While it has shown impressive year-to-date growth of 699.28%, the recent sharp decline raises concerns. The main risk is the negative earnings per share forecast, with a projected EPS of -0.54 for Q4 2024, which could impact investor sentiment.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.